The publication of important new long-term data from nearly 900 patients and a rapid evolution in the technology is putting entirely the Subcutaneous Implantable Cardioverter Defibrillator (S-ICD, Boston Scientific) at the heart of a monumental shift in the utilisation of devices for a broad range of patients at risk of sudden cardiac death, say early adopters of the technology. Cardiac Rhythm News traces the transformation of the utilisation of the S-ICD from the first implantation and indications to its current use.
